Rosenbot completes over 100 million RMB in Series B financing to accelerate the development of intelligent surgical robots

Recently, Beijing Rosenbot Technology Co., Ltd. announced the completion of a round B financing of over 100 million yuan, led by Beijing Zhongguancun Science Park and Shenzhen Capital Group, followed by Tsinghua Holdings China Merchants Fund and Shengjing Capital. Life Capital served as the exclusive financial advisor. This round of financing will be mainly used to accelerate the development of new surgical robot products, clinical registration, production expansion and global market promotion.

It is understood that Rosenbot was founded in 2017. It is the product of the cross-integration of medicine and engineering between Beijing University of Aeronautics and Astronautics and Beijing Jishuitan Hospital, focusing on original innovation of cutting-edge technologies in medical robots . The company is committed to creating a new generation of intelligent orthopedic surgical robot system with fracture reduction function. It is the first in the world to realize advanced technologies such as real-time 3D navigation, auxiliary fracture reduction operation, and automatic surgical planning during surgery, realizing intelligent surgical operations for the entire surgical process from closed fracture reduction to minimally invasive fixation.

Pelvic fracture closed reduction surgery faces two major challenges: the pelvic three-dimensional structure is difficult to fully display through intraoperative fluoroscopic images, and closed reduction requires precise position and posture adjustment under high load. In response to this clinical demand, Rosenbot has developed a new generation of intelligent orthopedic surgical robot system with fracture reduction function, including real-time three-dimensional intraoperative navigation of fractures, computer-assisted automatic planning, and robot autonomous reduction operation, realizing "letting the most difficult part be completed by the robot."

Wang Yu, founder of Rosenbot, said: "We hope to use digital means to 'copy' the rich experience of clinical experts and realize personalized surgical planning. Relying on a research and development path that combines strong medical and engineering, Rosenbot aims to create a basic universal software and hardware platform with core competitiveness. In the future, surgical robots will be a platform-based development path. Rosenbot will build a set of clinical demand-driven product innovation systems to support us in covering more clinical needs in the future. The rapid development of robotics technology is changing the concepts and models in the medical field. As an indispensable tool for minimally invasive surgery, robotic systems have the potential to reduce the total cost of social medical care and improve the accessibility of medical resources. It represents the future development direction of modern surgical technology."

The investment team of Tsinghua Holdings China Merchants Fund said: Medical and engineering intersection combines AI, sensors , robots and other hard technologies with medicine. Through intelligence and digitization, machines can learn doctors' skills and experience and present them stably, simplifying complex operations, making large operations minimally invasive, and popularizing medical resources. The intelligent pelvic reduction robot developed by Rosenbot and Jishuitan Hospital integrates advanced technologies such as automatic preoperative surgical planning, 3D real-time visual navigation during surgery, and precise force-position coordinated operation. It breaks through the limitations of doctors' "brain", "eyes" and "hands" in traditional surgery, making pelvic closed reduction surgery more "precise", "minimally invasive" and "intelligent". In clinical experiments, it even successfully completed a closed minimally invasive pelvic reduction surgery for a 92-year-old man. With the clinical and application promotion of the product, it will help improve the level of fracture trauma reduction treatment, replicate high-end surgical capabilities, expand the hospital's medical level, and benefit a large number of patients.